Capricor Therapeutics Inc
Change company Symbol lookup
Select an option...
CAPR Capricor Therapeutics Inc
MTG MGIC Investment Corp
PTTN Patten Energy Solutions Group Inc
MSFT Microsoft Corp
XOM Exxon Mobil Corp
CSCO Cisco Systems Inc
MRVL Marvell Technology Group Ltd
DHT DHT Holdings Inc
DLNG-A Dynagas LNG Partners LP
EEX Emerald Holding Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Price
Delayed
$5.40
Day's Change
0.005 (0.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.74
Day's Low
5.39
Volume
(Light)

Today's volume of 816,345 shares is on pace to be much lighter than CAPR's 10-day average volume of 2,770,922 shares.

816,345

Display:

Providers:

UpdateCancel
6 providers

No press release found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.